Pituitary Hormones

Vasopressin (ADH): The Water-Conserving Peptide

13 min read|March 25, 2026

Pituitary Hormones

9 amino acids

Vasopressin is a nine-amino-acid peptide that controls how much water your kidneys retain, playing a role in everything from blood pressure to social bonding.

Cuzzo et al., StatPearls, 2026

View as image

Vasopressin, also called antidiuretic hormone (ADH) or arginine vasopressin (AVP), is a nine-amino-acid peptide produced in the hypothalamus and released from the posterior pituitary gland. It is one of the most ancient signaling molecules in biology, with homologs found in species from insects to humans.^[1] Its primary function is straightforward: it tells your kidneys to hold onto water. Without it, humans would produce up to 20 liters of urine per day and die of dehydration within hours if unable to drink. For more on the pituitary gland's broader peptide hormone functions, see the pituitary gland: the peptide hormone headquarters.

But vasopressin does far more than conserve water. It constricts blood vessels, modulates stress responses through the hypothalamic-pituitary-adrenal (HPA) axis, and influences social behaviors including pair bonding and aggression. Its three receptor subtypes (V1a, V1b, V2) are distributed across the vascular system, brain, and kidneys, giving this small peptide an outsized role in human physiology.^[2]

Key Takeaways

Vasopressin acts on V2 receptors in the kidney collecting duct to insert aquaporin-2 water channels, concentrating urine and preventing dehydration (Cuzzo et al., StatPearls)
Osmoreceptors in the hypothalamus detect plasma osmolality changes as small as 2 mOsm/L, triggering vasopressin release within minutes (Cuzzo et al., StatPearls)
Desmopressin, the synthetic vasopressin analog, has been in clinical use for over 30 years with a favorable safety profile across multiple formulations (Vande Walle et al., 2007)
Diabetes insipidus, caused by vasopressin deficiency or receptor resistance, can produce urine output exceeding 20 liters per day (Mutter et al., 2021)
V1b receptor antagonists are being explored as treatments for depression, targeting the vasopressin-HPA axis connection (Kanes et al., 2023)
Vasopressin and oxytocin differ by only two amino acids but have divergent effects on social behavior, with vasopressin linked to aggression and territory defense (Manning et al., 2012)

How Vasopressin Controls Water Balance

Vasopressin's water-conserving mechanism centers on the V2 receptor, located on the basolateral membrane of principal cells in the kidney's collecting duct. When vasopressin binds V2, it triggers a signaling cascade through cyclic AMP and protein kinase A that causes aquaporin-2 (AQP2) water channels to migrate from intracellular storage vesicles to the apical (urine-facing) membrane of the cell.^[1]

With AQP2 channels in place, water moves passively from the dilute urine in the collecting duct into the hypertonic interstitial fluid of the kidney medulla, and from there back into the bloodstream. When vasopressin levels drop, AQP2 channels are internalized and water passes through the collecting duct unabsorbed, producing dilute urine.

This system responds to plasma osmolality with extraordinary sensitivity. Osmoreceptors in the hypothalamus (specifically in the organum vasculosum of the lamina terminalis and the subfornical organ) detect changes as small as 1-2% in blood solute concentration. A rise in osmolality above the set point of approximately 280 mOsm/L triggers vasopressin release. A drop below this threshold suppresses it. This feedback loop operates continuously, adjusting urine concentration in real time to maintain blood osmolality within a narrow range.^[1]

Volume depletion provides a second, independent trigger. Baroreceptors in the carotid sinus, aortic arch, and left atrium detect drops in blood pressure or blood volume and signal the hypothalamus to increase vasopressin secretion. This volume-mediated release can override osmolality signals; during severe hemorrhage, vasopressin levels rise dramatically even if blood osmolality is normal or low.

Beyond the Kidney: Vasopressin's Three Receptor Types

Vasopressin's diverse effects stem from three distinct receptor subtypes, each activating different intracellular pathways:^[2]

V1a receptors are found on vascular smooth muscle cells, hepatocytes, and platelets. Activation causes vasoconstriction (narrowing of blood vessels), glycogenolysis (glucose release from liver stores), and platelet aggregation. This is why vasopressin can raise blood pressure in emergencies and why it is used in vasodilatory shock when other vasopressors fail.

V1b receptors (also called V3) are concentrated in the anterior pituitary and brain. They stimulate ACTH release from corticotroph cells, placing vasopressin alongside corticotropin-releasing hormone (CRH) as a co-regulator of the stress response. V1b receptors are also expressed in limbic brain regions associated with emotion and aggression.^[4] For more on how ACTH drives cortisol production, see the dedicated article.

V2 receptors are the kidney receptors described above, responsible for water reabsorption.

This receptor diversity means vasopressin is not simply a "water hormone." It simultaneously regulates fluid balance, cardiovascular tone, and neuroendocrine stress responses. Synthetic analogues have been designed to selectively target specific receptor types, creating drugs with narrow therapeutic profiles from a broadly active natural peptide.^[3]

When Vasopressin Fails: Diabetes Insipidus

Diabetes insipidus (DI) occurs when vasopressin is either absent or ineffective. Despite the name, it has nothing to do with blood sugar or insulin. The "insipidus" refers to the tasteless nature of the large volumes of dilute urine produced, in contrast to the sweet urine of diabetes mellitus.^[5]

Two forms exist:

Central diabetes insipidus results from insufficient vasopressin production. The hypothalamus or posterior pituitary fails to synthesize or release adequate ADH, typically due to head trauma, pituitary surgery, tumors (especially craniopharyngiomas), autoimmune destruction, or genetic mutations in the vasopressin-neurophysin II gene. In rare familial forms, mutations cause the vasopressin precursor protein to misfold, gradually destroying the neurons that produce it.^[5]

Nephrogenic diabetes insipidus results from kidney resistance to vasopressin. The hormone is present at normal or elevated levels, but V2 receptors or AQP2 channels do not respond. Causes include lithium therapy (the most common acquired cause, affecting up to 40% of long-term lithium users), hypercalcemia, hypokalemia, and genetic mutations in the V2 receptor or AQP2 genes.

Both forms produce polyuria (urine output exceeding 50 mL/kg per day, or more than 3-4 liters in adults), polydipsia (extreme thirst), and nocturia (frequent nighttime urination). Untreated patients can lose 10-20 liters of water per day, making constant fluid intake essential for survival. Diagnosis involves water deprivation testing and measurement of copeptin, a stable surrogate marker for vasopressin that is easier to measure in blood.

Central DI is treated with desmopressin, a synthetic vasopressin analog. Nephrogenic DI is more challenging because the kidney cannot respond to vasopressin signaling; treatment relies on thiazide diuretics, NSAIDs, and addressing the underlying cause.

When Vasopressin Overacts: SIADH

The opposite of diabetes insipidus is the syndrome of inappropriate antidiuretic hormone secretion (SIADH), where vasopressin is released in excess despite low plasma osmolality. The kidneys reabsorb too much water, diluting blood sodium and causing hyponatremia.^[1]

Common causes include small cell lung cancer (which can produce ectopic vasopressin), central nervous system disorders (stroke, meningitis, traumatic brain injury), pulmonary diseases (pneumonia, tuberculosis), and medications (SSRIs, carbamazepine, opioids). The resulting hyponatremia can range from mild (nausea, headache) to life-threatening (seizures, coma, brain herniation).

Treatment of SIADH includes fluid restriction, hypertonic saline for severe cases, and vasopressin receptor antagonists called "vaptans." Tolvaptan, a selective V2 receptor antagonist, blocks vasopressin's action on the kidney, promoting water excretion without sodium loss. It represents one of the first peptide hormone receptor antagonists to achieve widespread clinical use.^[2]

Desmopressin: The Synthetic Workhorse

Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is the most widely used vasopressin analogue. Two modifications to the native peptide, removal of the amino group at position 1 and replacement of L-arginine with D-arginine at position 8, create a molecule with dramatically different properties:^[6]

Longer half-life: Desmopressin resists enzymatic degradation, lasting 6-24 hours versus vasopressin's 10-35 minutes
V2 selectivity: The modifications eliminate most V1a activity, removing the vasoconstriction and blood pressure effects
Multiple formulations: Available as intranasal spray (since 1972), injectable solution (1981), oral tablets (1987), and oral lyophilisate (2005)

A 30-year safety review by Vande Walle and colleagues, published in Current Drug Safety, analyzed both published literature and adverse event reports submitted to the manufacturer. The review found desmopressin to be generally well-tolerated across all formulations, with hyponatremia identified as the primary safety concern, manageable through proper dosing and fluid restriction guidelines.^[6]

Clinical applications of desmopressin include:

Central diabetes insipidus: First-line treatment, replacing absent vasopressin
Primary nocturnal enuresis: Reduces nighttime urine production in children with bedwetting
Nocturia in adults: Reduces overnight urine volume
Hemophilia A and von Willebrand disease: Stimulates release of von Willebrand factor and factor VIII from endothelial cells (a V1a-mediated effect that desmopressin retains at therapeutic doses)

Vasopressin and oxytocin are closely related peptides, differing by only two amino acids. Oxytocin is associated with bonding, trust, and nurturing behavior. Vasopressin's behavioral role is different: it is linked to territorial behavior, mate guarding, aggression, and social recognition, particularly in males.^[3]

Manning and colleagues reviewed the pharmacological tools available to study vasopressin and oxytocin systems, noting that selective agonists and antagonists for each receptor subtype have enabled researchers to disentangle these overlapping systems.^[3] For a deeper exploration of vasopressin's sister peptide, see oxytocin: far more than the "love hormone".

The V1b receptor's role in stress and mood has attracted pharmaceutical interest. Kanes and colleagues reviewed the evidence for targeting the vasopressin V1b receptor system in depression, noting that chronic stress elevates vasopressin expression in the hypothalamus and that V1b receptor antagonists show antidepressant-like effects in animal models.^[4] The V1b antagonist ABT-436 reduced plasma ACTH and cortisol in human trials and showed improvements on some symptom measures in major depressive disorder, though overall results were mixed. The heterogeneity of depression as a syndrome, with only some patients showing HPA axis dysregulation, may explain why a one-size-fits-all V1b approach has not produced clear-cut clinical benefits.

What Remains Unknown

Despite over 70 years of clinical use (synthetic vasopressin was first available in 1954), fundamental questions about this peptide remain open.

The precise role of vasopressin versus CRH in stress responses varies between acute and chronic stress, between sexes, and across psychiatric conditions. Whether V1b antagonists could benefit a biomarker-selected subgroup of depression patients with confirmed HPA axis hyperactivity has not been adequately tested.^[4]

How vasopressin interacts with its structural twin oxytocin at the receptor level is incompletely understood. Both peptides can bind each other's receptors at high concentrations, creating crosstalk that complicates the interpretation of pharmacological and behavioral studies.^[3]

The long-term consequences of chronic desmopressin use, particularly in children treated for nocturnal enuresis over multiple years, are tracked primarily through adverse event reporting rather than prospective long-term cohort studies.^[6]

Vasopressin's role in metabolic regulation is emerging. V1a and V1b receptor activation affects glucose metabolism and lipid handling, raising the question of whether vasopressin system dysfunction contributes to metabolic syndrome. Early-stage research on novel vasopressin analogues with metabolic effects suggests this peptide system has therapeutic potential beyond its established uses.^[2]

The Bottom Line

Vasopressin is a nine-amino-acid peptide with three distinct receptor types that control water balance, blood pressure, and stress responses. Clinical applications range from desmopressin for diabetes insipidus and enuresis to vaptans for SIADH. The peptide's role in social behavior and mood regulation is an active research area, with V1b receptor antagonists being tested for depression. For a hormone discovered decades ago, vasopressin continues to reveal new biological roles.

Frequently Asked Questions

Vasopressin acts primarily on V2 receptors in the kidney collecting duct, inserting aquaporin-2 water channels that allow water to be reabsorbed from urine back into the bloodstream. This concentrates urine and prevents dehydration. Vasopressin also constricts blood vessels via V1a receptors, stimulates ACTH release via V1b receptors, and modulates social behavior in the brain. Without vasopressin, humans would produce up to 20 liters of dilute urine per day.

Central diabetes insipidus is caused by insufficient vasopressin production, typically from head trauma, pituitary surgery, tumors, or autoimmune destruction of vasopressin-producing neurons. Nephrogenic diabetes insipidus is caused by kidney resistance to vasopressin, most commonly from lithium therapy (affecting up to 40% of long-term users), hypercalcemia, or genetic mutations in the V2 receptor or aquaporin-2 genes (Mutter et al., 2021).

They are opposite conditions. Diabetes insipidus involves too little vasopressin activity (either absent hormone or resistant kidneys), producing large volumes of dilute urine and causing dehydration. SIADH involves too much vasopressin, causing excessive water retention, dilute blood, and low sodium (hyponatremia). DI is treated with desmopressin; SIADH is treated with fluid restriction and vasopressin receptor antagonists like tolvaptan.

Desmopressin is a synthetic vasopressin analog prescribed for central diabetes insipidus, primary nocturnal enuresis (childhood bedwetting), adult nocturia, and bleeding disorders including hemophilia A and von Willebrand disease. It has been in clinical use since 1972, with a 30-year safety review finding it generally well-tolerated across intranasal, injectable, and oral formulations (Vande Walle et al., 2007). Hyponatremia is the primary safety concern.

Vasopressin and oxytocin are structurally similar peptides that differ by only two of their nine amino acids. Both are produced in the hypothalamus and released from the posterior pituitary. Oxytocin is associated with bonding and trust; vasopressin is linked to territorial behavior, mate guarding, and aggression. At high concentrations, each peptide can activate the other's receptors, creating biological crosstalk that researchers are still working to understand (Manning et al., 2012).

Vasopressin acts on V1b receptors in the brain to stimulate ACTH and cortisol release, connecting it to the stress response. Chronic stress increases vasopressin expression, and V1b receptor antagonists show antidepressant effects in animal models. In human trials, the V1b antagonist ABT-436 reduced cortisol levels and improved some depression symptoms, though overall results were mixed (Kanes et al., 2023). The heterogeneity of depression makes it difficult to demonstrate clear benefits from targeting a single pathway.